Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. - Wikidata - awgldk - TriplyDB

Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments.

Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments.

http://www.wikidata.org/entity/Q40452043

about

L-acetylcarnitine for treating fragile X syndrome L-acetylcarnitine for fragile X syndrome Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders Modeling Fragile X Syndrome Using Human Pluripotent Stem Cells The promise and perils of HDAC inhibitors in neurodegeneration Role of CTCF protein in regulating FMR1 locus transcription Improved methodology for assessment of mRNA levels in blood of patients with FMR1 related disorders Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome.Population- and family-based studies associate the MTHFR gene with idiopathic autism in simplex families.The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome.Epigenetic characterization of the FMR1 promoter in induced pluripotent stem cells from human fibroblasts carrying an unmethylated full mutation FMR1 epigenetic silencing commonly occurs in undifferentiated fragile X-affected embryonic stem cells Reversible histone methylation regulates brain gene expression and behavior.The FMR1 gene and fragile X-associated tremor/ataxia syndrome.Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells.SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome Implication of abnormal epigenetic patterns for human diseases.Genome-wide methylation analysis demonstrates that 5-aza-2-deoxycytidine treatment does not cause random DNA demethylation in fragile X syndrome cells.Epigenetics in nucleotide repeat expansion disorders.Bidirectional transcription of trinucleotide repeats: roles for excision repair.The biological effects of simple tandem repeats: lessons from the repeat expansion diseases.Epigenetics, autism spectrum, and neurodevelopmental disorders.Epigenetic regulation of gene expression in physiological and pathological brain processes.Emerging roles of epigenetic mechanisms in Parkinson's disease.The neurobiology of X-linked intellectual disability.Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development.DNA methylation: dynamic and stable regulation of memory.The FMR1 promoter is selectively hydroxymethylated in primary neurons of fragile X syndrome patients.Genetics and Epigenetics in Adult Neurogenesis.Defining the role of the CGGBP1 protein in FMR1 gene expression.DNA Methyltransferase Inhibitors: Development and Applications.Fragile X syndrome: an overview and update of the FMR1 gene.Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations.Epigenetic Aberration of FMR1 Gene in Infertile Women with Diminished Ovarian Reserve.Reevaluation of FMR1 Hypermethylation Timing in Fragile X Syndrome.Of Men and Mice: Modeling the Fragile X Syndrome.

P2860

Q24187914-E97580DA-D136-4A66-8A4E-FE06A6E9D0BA Q24201787-4560E291-49D8-46CB-A335-8FC006A347C2 Q24626017-669CE083-F39B-4FE9-B18A-2F8B2C3DDEAE Q26739927-76CB0D89-3939-4826-B33C-900F004B025E Q26740071-97E05EA0-BE12-4D49-99C1-4BE695022505 Q28080022-26CA5E58-03F3-4CE4-BB17-9DAA9296EA8B Q28087539-80F77827-F766-48AA-9159-3C686FDAD37E Q28534708-748EB347-6F23-489A-A61E-4B39BA1489E0 Q33463888-C4649BC0-8C7E-4700-BB6A-358BD2868901 Q33775485-8E512ECA-84A0-41B5-AB9C-DD559E15B506 Q34149181-44F1ECEE-13E0-4266-8765-6B0BAF97B3FA Q34275676-B620847C-1C41-4375-A069-B8742C5E291A Q34469474-94D3082C-773E-4601-B04F-0F7E5C60DFEA Q34530652-BCBCBF09-1407-4E4A-83C0-EE9017EBBC68 Q34879560-53149C9E-621B-491C-8217-9518B1673016 Q35061671-E65CD647-B86F-43BC-8026-236B29C2A095 Q35966957-4E15471D-CD99-4118-99F8-BE41FD4B4E71 Q36491908-E586FF25-2282-43BC-8F2A-38C5C15699E6 Q36498006-F93EE2D4-F38B-4D31-8ABD-379825B70AFA Q36549606-E6BCD29B-E486-4529-BC89-27E9597E2128 Q36626596-FCA732EB-C783-48E2-98E9-EACBFC087C46 Q36725163-36F9FA5F-9F1C-405B-8F63-984EC27DD641 Q36848454-32B8EF69-69AC-4FBD-9469-5D1D7AA8E4D1 Q37038917-69D5FC59-538E-407F-8890-69A65D7C6EE9 Q37204533-5DCD0CBF-849D-446F-ABB5-889E22C1D7A0 Q37249145-9BAC1A3A-DC9F-4912-B98D-368FA448B072 Q37870034-890FA688-A82A-48DE-B11C-CBC294F6A364 Q37926552-F0FF6D08-3F4D-4DA1-9AE5-E71F62B2AE5D Q38118810-B3FAE743-CFB0-4D88-826D-92F1D962BA25 Q38162720-9D8F0904-8344-44D1-8E79-38FF4CB65558 Q38472630-FA9566F5-1579-4144-BBCA-6BFA59A7B8F9 Q38760301-3FC6F3B7-136E-4E4E-9C07-AC1FAAB6CBAA Q38825010-FCEEB86F-798E-4032-8B3A-580EEC25C81C Q38840889-C2D73174-8231-4ACE-B3AD-610C26D42A5E Q39003558-013A774C-9CC9-4439-A08D-C603B2A3DF6B Q39375765-4367B54B-5753-4C0A-AFD2-60856C194243 Q39961107-B4FB40F0-44A1-4EE5-BF39-E820654C8578 Q47178654-E70123CE-D0B4-4AD7-BE52-51CE5E8FC510 Q50166708-60BEE612-9F62-480B-9079-FBC0DF3F117B Q53422584-2465C835-504A-44F9-97FE-1DC2F8451D4C

P2860

Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments.

http://www.wikidata.org/entity/Q40452043

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Differential epigenetic modifi ...... ng pharmacological treatments.

@en

type

label

Differential epigenetic modifi ...... ng pharmacological treatments.

@en

prefLabel

Differential epigenetic modifi ...... ng pharmacological treatments.

@en

P1433

Q40452043-20CEFE7F-692E-4D90-9140-9EF01AD5489B

P1476

Q40452043-07310C16-DF4B-4359-8388-446898B01354

P2093

Q40452043-401A3B31-6663-456E-B411-A633761D6388

Q40452043-6CD5A114-CCFC-4FC4-BC99-48B8AF4C0F73

Q40452043-6DCD01CD-37E3-4E39-B3D2-07F68DED1A2E

Q40452043-8A186DA9-8184-4477-B61F-ACED030377F0

Q40452043-ABC35860-5429-4C93-BB4D-5828BE37587E

Q40452043-FB36D265-1AED-4619-A1E6-CE94D2135856

P2860

Q40452043-06520FEB-AEAC-464C-AA13-A45B18785BA5

Q40452043-0CE95047-BDB4-4547-9ED7-A2EBA7CB240F

Q40452043-11461BBC-6F57-48D3-B1A5-46BCA7C40D3B

Q40452043-14153C9C-4F1C-44B7-BB4B-46F775A723BB

Q40452043-1D2BBE48-E686-4D78-B6D4-E73636E3BA9F

Q40452043-31627916-5348-4764-AF78-562B94C280C9

Q40452043-417B1556-96FB-41C8-8E86-844D8044962E

Q40452043-4C281C58-7595-4433-AEBB-B811938F6F7A

Q40452043-503C6CA8-251D-48FE-B973-59A6F0D7F1B9

Q40452043-53B0F8BC-D075-472A-8D1E-4513FA4608A8

P2888

Q40452043-ACC499D1-55A0-4C0E-B338-C8E6394EF9B6

P304

Q40452043-C2BAEACE-C974-4275-9755-B007C6661254

P31

Q40452043-C6DDC456-443F-4868-9A9A-E6D8D1700B83

P356

Q40452043-FE995F85-0337-4C74-B6CE-80F3FE60A824

P433

Q40452043-47AEC6D6-FAB1-4C89-8A87-26B2C924E96E

P478

Q40452043-7D0FF4E2-F5E6-483E-9057-4B3A40D18A36

P577

Q40452043-E9E4D05A-61C8-448C-98AD-5C5BBC09655E

P5875

Q40452043-877D64A6-8ABD-462A-B9FB-0AA52A014BAD

P6179

Q40452043-7A30A4A5-1FB3-440A-AEAC-C23FE453E3A2

P698

Q40452043-E23603AD-1000-4219-AC96-F57E4DD02813

P356

SJ.EJHG.5201393

P1433

European Journal of Human Genetics

P1476

Differential epigenetic modifi ...... ng pharmacological treatments.

@en

P2093

Ben A Oostra

http://www.w3.org/2001/XMLSchema#string

Elisabetta Tabolacci

http://www.w3.org/2001/XMLSchema#string

Giovanni Neri

http://www.w3.org/2001/XMLSchema#string

Pietro Chiurazzi

http://www.w3.org/2001/XMLSchema#string

Roberta Pietrobono

http://www.w3.org/2001/XMLSchema#string

Umberto Moscato

http://www.w3.org/2001/XMLSchema#string

P2860

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

CpG methylation, chromatin structure and gene silencing-a three-way connection.

Maintenance of stable heterochromatin domains by dynamic HP1 binding

Cellular memory and the histone code

Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox

Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome

Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription

Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome

Histone methylation in transcriptional control

Heterochromatin and epigenetic control of gene expression

P2888

sj.ejhg.5201393

P304

641-648

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.EJHG.5201393

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7991947

http://www.w3.org/2001/XMLSchema#string

P6179

1004367973

http://www.w3.org/2001/XMLSchema#string

P698

15741991

http://www.w3.org/2001/XMLSchema#string